期刊文献+

原发性腹膜恶性肿瘤的免疫组化研究及其预后的相关分析 预览 被引量:1

The predictive value of immunohistochemical markers for the prognosis of primary peritoneal malignancies.
在线阅读 下载PDF
收藏 分享 导出
摘要 目的:探讨原发性腹膜恶性肿瘤p53、Top2α、Ki-67和Her-2/neu的表达及其预测预后的价值.方法:对1995年5月至2005年5月在北京大学人民医院治疗的21例原发性腹膜恶性肿瘤患者的石蜡组织标本,用免疫组化技术检测p53、Top2α、Ki-67和Her-2/neu的表达,分析其与化疗疗效和生存时间的关系.结果:21例患者Top2α、Ki-67、p53阳性表达率均为52.4%(11/21),8例存在Top2α和Ki-67共表达;Her-2/neu全部呈阴性表达.Top2α与Ki-67表达呈显著的正相关,且均与肿瘤细胞分化等级呈显著正相关.铂类敏感组(10例)和耐药组(8例)p53阳性表达有统计学差异(3例 vs 7例,P=0.03).p53阳性表达和阴性表达者的中位无进展生存时间分别为15个月和47个月,两者比较有统计学差异;p53阳性表达对总生存时间以及Top2α、Ki-67阳性表达对中位无进展生存时间和总生存时间均无显著影响.结论:原发性腹膜恶性肿瘤组织中存在Top2α、Ki-67与p53的阳性表达,Top2α、Ki-67的表达与肿瘤细胞分化等级呈显著正相关,但对预后可能缺乏显著影响.p53阳性表达者中位无进展生存时间缩短,提示可能对铂类化疗耐药,预后可能较差. Objective: To investigate the expression of p53, Top2α, Ki-67 and Her-2/ neu in primary peritoneal malignancies,and their predictive value for the prognosis. Methods: Immunohistochemistry was used to determine the expressions of p53, Top2α ( topoisomerase Ⅱ- alpha) ,Ki-67 and Her-2/neu in 21 cases of primary peritoneal malignancies treated in the People's Hospital,Peking University between May 1995 and May 2005. The effect of these markers on the chemotherapy response and survival was analyzed. Results: The expressions of p53, Top2α,Ki-67 were all demonstrated in 11 cases, and 8 cases showed the expression of both Top2α and Ki-67. None showed the expression of Her-2/neu. The expression of Top2α was sig- nificantly correlated with that of Ki-67, and both had significant positive correlations with histological grade. None of the expression of t)53, Top2α, Ki-67 showed a correlation with stage. A significant difference in expression of t)53 was found between the platinum-sensitive group and the platinum-resistant group. The median progression-free survival of patients with positive p53 immunostaining was 15 months,which was significantly shorter than that of patients with negative p53 immunostaining (47 months) (P 〈 0.05 ). No obvious effect of p53 expression was observed on the overall survival. And no significant effect of Top2α and Ki-67 expression was shown either on the progression-free survival or overall survival. Conclusion:p53, Top2ct, Ki-67 are expressed in primary peritoneal neoplasms. The expression of Top2α and Ki-67 have a positive correlation with histological grade, yet neither has effect on the progression-free survival or overall survival. The median progression-free survival of patients with positive p53 immunostaining is decreased, probably suggesting a resistance to platinum-based chemotherapy and a poor prognosis.
作者 张超 崔恒 沈丹华 虞有智 李艺 祝洪澜 梁旭东 李小平 陈定宝 魏丽惠 Zhang Chao, Cui Heng, Shen Danhua, et al. (1.People's Hospital, Peking Universityl. Department of Gynecological Oneology Center ;2. Department of Pathology, Beiiing)
出处 《现代妇产科进展》 CSCD 北大核心 2007年第4期 289-293,I0001,共6页 Current Advances In Obstetrics and Gynecology
关键词 腹膜肿瘤 基因 p53 DNA拓扑异构酶类Ⅱ型 抗原 Ki-67 基因 HER-2 预后 Peritoneal neoplasms Genes, p53 DNA Topoisomerases, type Ⅱ Antigens, Ki-67 Genes, HER-2 Prognosis
作者简介 张超(1977-),女,北京大学人民医院妇产科主治医师。主要研究方向:卵巢恶性肿瘤、免疫治疗。 通讯作者 Email:cuiheng20@tom.com
  • 相关文献

参考文献22

  • 1Bloss JD,Liao SY,Buller RE,et al.Extraovarian peritoneal serous papillary carcinoma:a case-control retrospective comparison to papillary adenocarcinoma of the ovary[J].Gynecol Oncol,1993,50:347-351 被引量:1
  • 2Eltabbakh GH,Werness BA,Piver S,et al.Prognostic factors in extraovarian primary peritoneal carcinoma[J].Gynecol Oncol,1998,71:230-239 被引量:1
  • 3张超 ,崔恒 ,赵彦 ,梁旭东 ,王朝华 ,李小平 ,沈丹华 ,王世军 ,魏丽惠 .原发性腹膜恶性肿瘤的治疗及预后分析[J].中华妇产科杂志,2005,40(7):464-468. 被引量:14
  • 4张超 ,崔恒 ,赵彦 ,梁旭东 ,王朝华 ,李小平 ,沈丹华 ,王世军 ,魏丽惠 .原发性腹膜恶性肿瘤化疗方案的探讨[J].中国妇产科临床杂志,2005,6(5):326-330. 被引量:1
  • 5Friedrichs K,Gluba S,Eidtmann H,et al.Overexpression of p53 and prognosis in breast cancer[J].Cancer,1993,72:3641-3647 被引量:1
  • 6Halperin R,Zehavi S,Hadas E,et al.Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma[J].Int J Gynecol Pathol,2001,20:341-345 被引量:1
  • 7Moll UM,Valea F,Chumas J.Role of p53 alteration in primary peritoneal carcinoma[J].Int J Gynecol Pathol,1997,16:156-162 被引量:1
  • 8Soslow RA,Slomovitz BM,Saqi A,et al.Tumor suppressor gene,cell surface adhesion molecule,and multidrug resistance in Mullerian serous carcinomas:clinical divergence without immunophenotypic differences[J].Gynecol Oncol,2000,79:430-437 被引量:1
  • 9Kowalski LD,Kanbour AI,Price FV,et al.A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma[J].Cancer,1997,79:1587-1594 被引量:1
  • 10Bosari S,Viale G,Radaelli U,et al.p53 accumulation in ovarian carcinomas and its prognostic implications[J].Hum Pathol,1993,24:1175-1179 被引量:1

二级参考文献29

  • 1张超 ,崔恒 ,赵彦 ,梁旭东 ,王朝华 ,李小平 ,沈丹华 ,王世军 ,魏丽惠 .原发性腹膜恶性肿瘤的治疗及预后分析[J].中华妇产科杂志,2005,40(7):464-468. 被引量:14
  • 2[1]Fromm GL, Gershenson DM, Silva EG, et al. Papillary serous carcinoma of the peritoneum. Obstet Gynecol, 1990, 75:89-95. 被引量:1
  • 3[2]Bloss JD, Liao SY, Buller RE, et al. Extraovarian peritoneal serous papillary carcinoma:a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol, 1993, 50: 347-351. 被引量:1
  • 4[4]Lauchlan SC. The secondary Mullerian system. Obstet Gynecol Surv, 1972, 27: 133-146. 被引量:1
  • 5[5]Swerdlow M. Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary : case report. Am J Obstet Gynecol, 1959, 77: 197-200. 被引量:1
  • 6[6]Eltabbakh GH, Werness BA, Piver S, et al. Prognostic factors in extraovarian primary peritoneal carcinoma. Gynecol Oncol, 1998, 71: 230-239. 被引量:1
  • 7[7]Mcguire WP, Hoskins WJ, Brady MF, et al. Cycolphosphamide and cisplatin compared with paclitaxel in patients with stage Ⅲ and IV ovarian cancer. N Engl J Med, 1996, 334: 1-6. 被引量:1
  • 8[8]Menzin AW, Aikins JK, Wheeler JE, et al. Surgically documented responses to paclitaxel and cisplatin patients with primary peritoneal carcinoma. Gynecol Oncol, 1996, 62: 55-58. 被引量:1
  • 9[9]Bloss JD, Brady MF, Liao SY, et al. Extraovarian peritoneal serous papillary carcinoma: a phase Ⅱ trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study. Gynecol Oncol, 2003, 89: 148-154. 被引量:1
  • 10[10]Piver MS, Eltabbakh GH, Hempling RE, et al. Two sequential studies for primary peritoneal carcimoma:induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin. Gynecol Oncol, 1997, 67: 141-146. 被引量:1

共引文献13

同被引文献24

  • 1国巍,马晓艳,刘爱民,姚敏.原发性腹膜浆液性伴移行细胞癌的病理特点——附1例报告[J].吉林医药学院学报,2010(1):50-52. 被引量:1
  • 2娄越亮 ,王雁飞 ,包乐纹 ,张燮良 .原发性腹膜癌的诊断与治疗进展[J].中国肿瘤临床,2005,32(4):236-240. 被引量:9
  • 3陈华,黄建瑾.原发性腹膜癌病因及治疗进展[J].中国实用妇科与产科杂志,2006,22(6):466-468. 被引量:5
  • 4曹泽毅.中华妇产科学[M].北京:人民卫生出版社,1999.2129. 被引量:3400
  • 5Fromm GL, Gershenson DM, Silva EG. Papillary serous carcinoma of the peritomeum [J ]. Obstect Gynecol, 1990,75 ( 1 ) : 89-95. 被引量:1
  • 6Swerdlow M. Mesothelioma of the pelvic peritoneum resembling Papillary cystadenocarcinoma of the ovary case report [J]. Am J Obstet Gynecol, 1959,77 : 197-200. 被引量:1
  • 7Bloss JD,Liao SY,Buller RE, et al. Extraovarian peritoneal serous papillary carcinoma:a case-control retrospective comparison to papillary adenocareinoma of the ovary[J]. Gyneeol Oncol, 1993, 50:347-351. 被引量:1
  • 8林志春,尹亮,何滔,等.18F-FDGPET/CT对原发性腹膜浆液性乳头状癌的诊断价值[A].中国核学会.第九届中国核学会"核科技、核应用、核经济(三核)"论坛论文集[C].中国核学会,2012:273-280. 被引量:1
  • 9Lessard-Anderson CR, Handlogten KS, Molitor RJ, et al. Effect of Tubal Sterilization Technique on Risk of Serous Ovarian and Primary Peritoneal Carcinoma [ J ]. Gynecol Oncol, 2014, 10 : 1-5. 被引量:1
  • 10Hynninen J, Lavonius M, Oksa S, et al. Is perioperative visual estimation of intra abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy[J]. Gynecol Oncol,2013,128(2) :229-232. 被引量:1

引证文献1

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈